# Rajiv Nayar

List of Publications by Year
in descending order



| 33 | 1,171 | 361413 | 395702 |
|---|---|---|---|
| papers | citations | 20 h-index | 33 g-index |

| 34 | 34 | 34 | 1065 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique. Biochimica Et Biophysica Acta - Biomembranes, 1989, 986, 200-206. | 2.6 | 172 |
| 2 | Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1023, 133-139. | 2.6 | 95 |
| 3 | Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry, 1985, 24, 5967-5971. | 2.5 | 85 |
| 4 | Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemotherapy and Pharmacology, 1993, 33, 17-24. | 2.3 | 77 |
| 5 | Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemotherapy and Pharmacology, 1990, 27, 13-19. | 2.3 | 65 |
| 6 | Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemotherapy and Pharmacology, 1994, 34, 137-146. | 2.3 | 53 |
| 7 | Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. British Journal of Cancer, 1995, 71, 482-488. | 6.4 | 53 |
| 8 | Impact of bulking agents on the stability of a lyophilized monoclonal antibody. European Journal of Pharmaceutical Sciences, 2009, 38, 29-38. | 4.0 | 53 |
| 9 | Effect of buffer species on the thermally induced aggregation of interferon-tau. Journal of Pharmaceutical Sciences, 2006, 95, 1212-1226. | 3.3 | 48 |
| 10 | Noninvasive Determination of Protein Conformation in the Solid State Using Near Infrared (NIR) Spectroscopy. Journal of Pharmaceutical Sciences, 2005, 94, 2030-2038. | 3.3 | 46 |
| 11 | Quantification of glycine crystallinity by near-infrared (NIR) spectroscopy. Journal of Pharmaceutical Sciences, 2004, 93, 2439-2447. | 3.3 | 38 |
| 12 | Stability of a Trivalent Recombinant Protein Vaccine Formulation Against Botulinum Neurotoxin During Storage in Aqueous Solution. Journal of Pharmaceutical Sciences, 2009, 98, 2970-2993. | 3.3 | 37 |
| 13 | Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. Experimental Cell Research, 1990, 190, 69-75. | 2.6 | 36 |
| 14 | Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems. Biochimica Et Biophysica Acta - Biomembranes, 1984, 777, 343-346. | 2.6 | 32 |
| 15 | Arrest and Retention of Multilamellar Liposomes in the Brain of Normal Mice or Mice Bearing Experimental Brain Metastases. Selective Cancer Therapeutics, 1989, 5, 73-79. | 0.5 | 29 |
| 16 | Solution behavior of a novel type 1 interferon, interferon-Ï„. Journal of Pharmaceutical Sciences, 2005, 94, 2703-2715. | 3.3 | 27 |
| 17 | Second virial coefficient determination of a therapeutic peptide by self-interaction chromatography. Biopolymers, 2006, 84, 527-533. | 2.4 | 26 |
| 18 | Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. Journal of Pharmaceutical Sciences, 2009, 98, 2994-3012. | 3.3 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulmonary Pharmacology and Therapeutics, 2010, 23, 107-114. | 2.6 | 22 |
| 20 | Binding of Liposomes to Human Bladder Tumor Epithelial Cell Lines: Implications for an Intravesical Drug Delivery System for the Treatment of Bladder Cancer. Selective Cancer Therapeutics, 1989, 5, 147-155. | 0.5 | 20 |
| 21 | Feasibility of Tissue Plasminogen Activator Formulated for Pulmonary Delivery. Pharmaceutical Research, 2005, 22, 1700-1707. | 3.5 | 19 |
| 22 | Effect of pH on Stability of Recombinant Botulinum Serotype A Vaccine in Aqueous Solution and During Storage of Freezeâ€Dried Formulations. Journal of Pharmaceutical Sciences, 2008, 97, 5132-5146. | 3.3 | 18 |
| 23 | Effects of solution conditions and surface chemistry on the adsorption of three recombinant botulinum neurotoxin antigens to aluminum salt adjuvants. Journal of Pharmaceutical Sciences, 2007, 96, 2375-2389. | 3.3 | 15 |
| 24 | The systemic activation of macrophages by liposomes containing immunomodulators. Seminars in Immunopathology, 1985, 8, 413-428. | 4.0 | 14 |
| 25 | Infrared spectroscopic studies of protein formulations containing glycine. Journal of Pharmaceutical Sciences, 2004, 93, 1359-1366. | 3.3 | 13 |
| 26 | High Throughput Formulation: Strategies for Rapid Development of Stable Protein Products. Pharmaceutical Biotechnology, 2002, 13, 177-198. | 0.3 | 12 |
| 27 | ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELLâ€TOLERATED IN MICE. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 1454-1460. | 1.9 | 9 |
| 28 | N-Succinyldioleoylphosphatidylethanolamine: structural preferences in pure and mixed model membranes. Biochimica Et Biophysica Acta - Biomembranes, 1988, 937, 31-41. | 2.6 | 8 |
| 29 | A microassay for the rapid and selective binding of cells from solid tumors to mouse macrophages. Cancer Immunology, Immunotherapy, 1986, 22, 125-31. | 4.2 | 7 |
| 30 | Characterization of Liposomes Containing the Chemotactic Peptide N-formyl-methionylleucyl-phenylalanine (FMLP) and Their Interaction with Mouse Macrophages. Cancer Drug Delivery, 1987, 4, 233-244. | 0.7 | 7 |
| 31 | In vitro activation of tumoricidal properties in mouse macrophages using the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) incorporated in liposomes. Cancer Immunology, Immunotherapy, 1988, 27, 1-6. | 4.2 | 6 |
| 32 | [42] Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties. Methods in Enzymology, 1986, 132, 594-603. | 1.0 | 4 |
| 33 | A Novel Method for Removing Residual Acetone from Gelatin Microspheres. Pharmaceutical Development and Technology, 2002, 7, 169-180. | 2.4 | 2 |